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Abstract:  To  investigate  whether  the  JAK-STAT  (Janus  kinase-signal  transducers  and 
activators  of  transcription)  pathway  participates  in  the  regulation  of  APOBEC3G 
(Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) gene transcription 
and to study the molecular mechanisms of interferon resistance in patients with chronic 
hepatitis B (CHB), changes in APOBEC3G and STAT-1 expression levels in HepG2.2.15 
cells after treatment with various concentrations of IFN-, were detected using real-time 
RT-PCR  and  Western-blot.  In  addition,  the  differences  in  STAT-1  and  APOBEC3G 
expression in liver tissues were also observed in patients with different anti-viral responses 
to IFN-. It is found that IFN- suppressed HBV replication and expression markedly in 
HepG2.2.15  cells,  and  simultaneously  enhanced  APOBEC3G  expression  in  a  dose-  or 
time-dependent manner within a certain range. Moreover, a corresponding gradual increase 
in STAT-1 expression levels was also observed. The expression levels of STAT-1 and 
APOBEC3G  in  the  liver  of  CHB  patients  with  a  complete  response  to  IFN-  are 
significantly higher than that of the patients with non-response to IFN- treatment. It is 
suggested  that  inducing  intracellular  APOBEC3G  expression  may  be  one  of  anti-HBV 
mechanisms  of  IFN-,  and  IFN--induced  APOBEC3G  expression  may  be  via  the 
JAK-STAT  signaling  pathway.  Moreover,  interferon  resistance  may  be  related  to  the 
down-regulation of STAT-1 expression in the patients who had non-response to IFN- 
treatment. 
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Apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC) family members consist 
of  a  series  of  cytidine  deaminases,  including  APOBEC1,  -2,  -3A,  -3B,  -3C,  -3E,  -3F,  -3G  and 
activation-induced  cytidine  deaminase  (AID).  APOBEC3G,  a  protein  member  of  the  APOBEC 
superfamily, has been suggested to play an important role in innate anti-viral immunity. APOBEC3G is 
expressed markedly in liver [1]. APOBEC3G can induce nucleoside mutations from deoxycytidine to 
deoxyuridine in the viral genome [2]. APOBEC3G has been identified as an intrinsic factor able to 
restrict replication of human immunodeficiency virus type 1 (HIV-1) lacking the viral accessory protein 
Vif  [3,4].  Recently,  it  has  been  revealed  that  APOBEC3G  also  inhibits  hepatitis  B  virus  (HBV) 
replication in cultured human hepatocytes [5–8]. However, the expression level of APOBEC3G is 
normally low in the human liver [9]. Thus, the role of APOBEC3G protein in host cell defenses against 
HBV infection in human hepatocytes remains unclear. 
Interferon-alpha (IFN-) is a main cytokine induced in the innate immune response directed against 
viral infection [10]. IFN- is rapidly induced with a high expression level and secreted into the blood 
circulation in response to viral infection in many types of cells, and then binds to a specific cell surface 
receptor and triggers intracellular reactions that lead to the transcriptional induction of IFN-stimulated 
genes (ISGs) [11]. The expression products of ISGs are many kinds of antiviral proteins including 
dsRNA-activated protein kinase (PKR), GBP-2, MxA, RANTES, and 2-5' oligoadenylate synthetase 
(OAS) [12], which are able to inhibit viral replication at the levels of penetration, uncoating, mRNA 
synthesis, protein synthesis, or assembly [13]. Currently, IFN- is widely used for the treatment of 
chronic  HBV  infection  [14].  However,  the  molecular  mechanisms  of  IFN-  suppression  of  HBV 
replication in hepatocytes remain poorly understood. 
IFN-mediated signal transduction and transcriptional activation is performed mainly through the 
Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling pathway [15]. It 
has been shown that STAT type 1 (STAT-1) is a critical molecule that plays a role of molecular 
messenger  in  the  JAK-STAT  signaling  pathway,  any  regional  damages  of  which  may  reduce  the 
antiviral efficacy of IFN- [16]. 
In  the  present  study,  we  observed  changes  in  APOBEC3G  and  STAT-1  expression  levels  in 
HepG2.2.15 cells after treatment with various concentrations of IFN-. With different responses to 
antiviral therapy with IFN-, the differences of STAT-1 expression in the liver tissues of patients with 
chronic hepatitis B were observed, in order to investigate whether the JAK-STAT signal pathway 
participates in the regulation of APOBEC3G gene transcription and to study the molecular mechanisms 
of IFN resistance in patients with chronic hepatitis B.  
2. Materials and Methods 
2.1. Cell Culture and IFN- Stimulation 
The HepG2.2.15 cell line was transfected with a plasmid containing two head-to-tail dimers of the 
hepatitis B virus (HBV) genome, which can secrete HBV DNA, HBsAg and HBeAg into medium stably 
and continuously in the course of cell culture [17]. HepG2.2.15 cells were conventionally cultured in 
Dulbecco's modified Eagle's medium (DMEM, GIBCO/BRL Co., USA) supplemented with 10% fetal Int. J. Mol. Sci. 2010, 11                         
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bovine  serum  (FBS,  GIBCO/BRL  Co.,  USA),  4  mmol/L  L-glutamine,  100  U/mL  penicillin  and 
100 μg/mL streptomycin under a humidified atmosphere of 5% CO2 at 37 ° C. HepG2.2.15 cells were 
seeded into 12-well plates at a density of 5 ×  10
5 cells per well in DMEM supplemented with 10% FBS, 





4 U/mL) for 8 hours, or with IFN- of 10
3 U/mL for 2, 4, 6, 8, 10, 12 hours. The cells and 
culture supernatants were collected for subsequent experiments at each time point. Every five-culture 
well was set for each treatment.  
2.2. Detection of HBsAg, HBeAg and HBV DNA in Culture Medium 
After HepG2.2.15 cells were treated with 10
4 U/mL IFN- for 8 hours, HBsAg and HBeAg in the 
culture medium were measured quantitatively by electrochemiluminescence immunoassay (ECLIA) 
(Elecsys 2010, Roche Diagnostics Shanghai Ltd.). HBV DNA in culture medium was also detected by 
real-time fluorescent quantitative PCR (Lightcycler, Roche Diagnostics Shanghai Ltd.).  
2.3. Patients and Liver Tissue Specimens 
Thirteen patients with chronic hepatitis B (CHB) were selected from the clinic or hospitalization unit 
at the department of infectious diseases, Renmin Hospital of Wuhan University during February 2008 
and October 2009. All patients enrolled fulfilled the following criteria before antiviral therapy with 
recombinant human IFN--2b: alanine aminotransferase (ALT) ranged from 80 to 400 U/L, normal total 
bilirubin (TBil), HBV DNA ranged from 10
5 to 10
7 copies/mL, and positive HBsAg and HBeAg. All 
patients  were  treated  with  recombinant  human  IFN--2b  (trade  name:  Andafen,  Anhui  Anke 
Biotechnology (Group) Co., Ltd, China), which was injected intramuscularly at a dose of 5 MU three 
times a week for 24 weeks. Among the total patients, 5 cases had complete response to IFN- therapy (as 
group A) and 8 patients had non-response to IFN- treatment (group B). The criteria of a complete 
response to IFN-treatment were HBV DNA loads <5 ×  10
2 copies/mL, HBeAg serum conversion, and 
normal ALT. The criteria of non-response to IFN-treatment were HBV DNA loads decrease ≤3 1og10 or 
increase without HBeAg serum conversion, and ALT > 40 U/L. There were no statistical differences in 
HBV DNA loads and ALT level between the patients of the two groups before treatment. All patients 
were genotype C. The patients of both groups were all male, aged 18–42 years with a median age of  
26 years.  Liver tissue samples were obtained from the patients via percutaneous Menghini needle 
extraction after antiviral treatment with IFN-. Small portions of the livers were kept frozen at −80 ° C 
for reverse transcriptase-polymerase chain reaction (RT-PCR) or Western blot. Other portions were 
separated and immersed in 10% buffered formalin solution for histological examination. Informed 
consent of the patients was obtained in accordance with institutional guidelines and the local ethics 
committee. 
2.4. Histopathological Examination 
Liver specimens were fixed in 10% formaldehyde for 12–24 hours, embedded in paraffin, sliced into 
sections of 5 μm thickness and stained with hematoxylin and eosin (H&E) to evaluate the pathological 
changes of liver tissue under light microscope.  Int. J. Mol. Sci. 2010, 11                         
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2.5. Real-Time RT-PCR 
RNA was isolated from the HepG2.2.15 cells collected at each time point by using TRIzol reagent 
(Invitrogen Co., USA). Residual DNA was removed from the RNA sample by using the DNAFREE 
RNA  Kit  (Zymo  Research  Corporation,  USA).  The  amount  of  RNA  was  quantified  by  using  a 
RiboGreen
® RNA Quantitation Kit (Molecular Probes, Inc., USA). Two microgram of total cellular 
RNA was reverse-transcribed into single-stranded complementary DNA (cDNA) by using a random 
primer hexamer (Promega Corporation, USA) and a MultiScribe™ Reverse Transcriptase (Applied 
Biosystems, USA) in a two-step RT-PCR reaction. The APOBEC3G, STAT-1 and HBV mRNA levels 
were determined in a real-time PCR with the SYBR Green I (Applied Biosystems, USA) by using 
LightCycler (Roche Diagnostics Shanghai Ltd.). GAPDH was used as a reference housekeeping gene 
and an internal control. Primers were designed using the Primer Express program (PerkinElmer Inc., 
USA) according to the nucleotide sequence from GenBank. The primers for APOBEC3G (284 bp) were 
forward 5-GCT GTG CTT CCT GGA CGT GA-3 and reverse 5-GGT GGT CCA CAA AGG TGT 
CCC-3; for STAT-1 (200 bp) were forward 5-CGA AGA GCG ACC AAA AAC AG-3 and reverse 
5-TGC TGG AAG AGG AGG AAG GT-3; for HBV (294 bp) were forward 5-CTT CAT CCT GCT 
GCT ATG-3 and reverse 5-CAC TGA ACA AAT GGC AC-3; for GAPDH (238 bp) were forward 
5-TTC ACC ACC ATG GAG AAG GC-3 and reverse 5-GGC ATG GAC TGT GGT CAT GAG-3. 
Thermal cycling conditions included pre-incubation at 50 ° C for 2 min, 95 ° C for 10 min followed by 
35 cycles of 94 ° C for 20 s, 54 ° C for 30 sec, 72 ° C for 30 s. LightCycler collected data automatically and 
analyzed the value of Threshold Cycle (Ct). The fold changes of APOBEC3G, STAT-1 and HBV 
mRNA expression were detected by using 2
-ΔΔCt method [18]. 
The mRNA levels of STAT-1 and APOBEC3G in the patients who had different responses to 
IFN-treatment were also determined by real-time RT-PCR with the same methods as mentioned above 
from approximate 100 mg of frozen liver tissue specimens.  
2.6. Western Blot Assay 
HepG2.2.15 cells collected at each time point were lysed in cold RIPA buffer (Pierce Biotechnology, 
Inc., USA), supplemented with Halt™ Protease Inhibitor Cocktail (Pierce Biotechnology, Inc., USA). 
Whole cell lysates were obtained by subsequent centrifugation at 15,000 ×  g for 10 min at 4 ° C. Protein 
concentrations were determined by using Bradford Protein Assay Kit with bovine serum albumin (BSA) 
as standard (SinoBio Biotech Co., Ltd. Shanghai, China). 50 μg of protein extracts were subjected to 
12% SDS-PAGE and then transferred to a Protran
® nitrocellulose membrane (Schleicher & Schuell 
BioScience GmbH, Whatman Group, Germany). The membrane was incubated with primary antibody 
(rabbit  anti-human  APOBEC3G  polyclonal  antibody,  Aviva  Systems  Biology  Co.,  USA;  or  rat 
anti-human STAT-1 monoclonal antibody, Santa Cruz Co., USA) at 4 ° C overnight after blocking with a 
10% BSA solution. The membrane was washed with tris-buffered saline Tween (TBST) buffer and then 
incubated  with  a  secondary  antibody  (goat  anti-rabbit  or  goat  anti-rat  horseradish  peroxidase 
(HRP)-conjugated IgG, Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) for 2 hrs at 
room  temperature,  and  finally  detected  by  chemiluminescence  using  Enhanced  NuGlo™ 
Chemiluminescent Substrate Kit (Alpha Diagnostic Intl. Inc., USA) followed by autoradiography and 
densitometry analysis. Membranes were also probed for β-actin as additional loading control. Int. J. Mol. Sci. 2010, 11                         
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One hundred milligram of liver tissue samples from the patients who had different responses to 
IFN-treatment were crushed in a liquid nitrogen-cooled grinding bowl, and protein levels of STAT-1 and 
APOBEC3G in liver were tested by Western blot using the same methods as mentioned above. 
2.7. Statistical Analysis 
All data were presented as means ±  SD. Differences among groups were assessed by using unpaired 
Student t test and one-way ANOVA. P value less than 0.05 was considered to be statistically significant. 
Calculations were performed with the SPSS version 13.0 statistical software package (SPSS, Chicago, 
USA). 
3. Results 
3.1. Changes in APOBEC3G Expression in HepG2.2.15 Cells 
Figure 1. APOBEC3G expression in HepG2.2.15 cells in response to IFN- stimulation. 
(A) RT-PCR electrophotogram of APOBEC3G mRNA after HepG2.2.15 cells were treated 
with various concentrations and times of IFN-; (B) Detection of APOBEC3G mRNA by 
real-time fluorescent quantitative RT-PCR after HepG2.2.15 cells were treated with various 





for 8 hours; (C) Detection of APOBEC3G mRNA by real-time fluorescent quantitative 
RT-PCR after HepG2.2.15 cells were treated with IFN- of 10
3 U/mL for 2, 4, 6, 8, 10, 
12 hours; (D) Detection of APOBEC3G protein by Western-blot after HepG2.2.15 cells 
were treated with various concentrations of IFN- for 8 hours. 
 
RT-PCR  quantitation  results  revealed  that  the  APOBEC3G  mRNA  levels  were  very  low  in 
HepG2.2.15  cells  without  IFN-  treatment.  However,  APOBEC3G  mRNA  levels  significantly 
increased (36-fold) in HepG2.2.15 cells with 10
4 U/mL IFN- treatment. When the concentration of 




4 U/mL, the APOBEC3G mRNA level in HepG2.2.15 cells was the highest, which had a 
statistical  difference  compared  with  HepG2.2.15  cells  treated  with  10
3 U/mL  (36.658  ±   2.625  vs. 
19.565 ±  1.564, t = 12.509, P < 0.01) (Figure 1A, B). With the prolongation of IFN- stimulation time, 
APOBEC3G mRNA level in HepG2.2.15 cells rose, reaching a peak at 8 hours, which had a statistical 
difference  compared  with  6  hours  (18.423  ±   1.205  vs.  12.356  ±   0.695,  t = 9.752,  P  <  0.01). 
Subsequently, APOBEC3G mRNA level decreased gradually, and there was no statistical difference in 
APOBEC3G mRNA level between 10 hours and 6 hours (11.375 ±  0.878 vs. 12.356 ±  0.695, t = 1.959, 
P > 0.05) (Figure 1A, C). The results of Western blot assays further showed a dose-dependent effect of 
IFN- on APOBEC3G protein expression (Figure 1D). 
3.2. Changes in STAT-1 Expression in HepG2.2.15 Cells 
The results of both real-time RT-PCR and Western blot assays showed that the expression levels of 
STAT-1  mRNA  and  protein  increased  with  an  increasing  stimulus  concentration  of  IFN-  in 
HepG2.2.15 cells, which was consistent with the change trends of the dose-dependent increase in 
APOBEC3G expression (Figure 2). 
Figure 2. STAT-1 expression in HepG2.2.15 cells after IFN- stimulation. (A) Detection of 
STAT-1 mRNA by real-time fluorescent quantitative RT-PCR after HepG2.2.15 cells were 
treated  with  various  concentrations  of  IFN-;  (B)  Detection  of  STAT-1  protein  by 
Western-blot after HepG2.2.15 cells were treated with various concentrations of IFN- for 
8 hours. 
 
3.3. Changes in HBV Replication and Expression in HepG2.2.15 Cells 
When HepG2.2.15 cells were treated with 10
4 U/mL IFN- for 8 hours, the levels of HBsAg, HBeAg 
and HBV DNA in culture medium, and HBV mRNA in cells were all significantly lower than that of 
HepG2.2.15 cells without IFN- stimulation (Table 1). This suggests that IFN- suppressed HBV 
replication and expression significantly in HepG2.2.15 cells.  Int. J. Mol. Sci. 2010, 11                         
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Table 1. Changes in the levels of HBV replication and expression in HepG2.2.15 cells 











0 U/mL IFN- for 8 h  5.92 ±  0.05  10.44 ±  0.16  6.32 ±  0.15  1.00 
10
4 U/mL IFN- for 8 h  2.37 ±  0.04  5.41 ±  0.08  3.45 ±  0.28  0.41 ±  0.13 
3.4. Histopathological Changes in the Liver of CHB Patients Wth Different Responses to IFN- 
The liver tissue of the patients in group A (complete response to IFN-) had a near normal hepatic 
lobule  structure,  which  showed  that  hepatocytes  were  not  degenerated  or  necrotic,  and  arrayed 
radiatively around the central vein, the Disse cavity was clear and well-distributed, and there was no 
obvious  periportal  inflammatory  cell  infiltration.  The  liver  tissue  of  the  patients  in  group  B 
(non-response to IFN-) showed hepatocytes with degeneration in the hepatic lobule, and periportal 
inflammatory cell infiltration was obvious (Figure 3). 
Figure 3. Representative light microscopy images of liver tissue stained with from the 
patients  who  had  complete  response  or  no  response  to  IFN-  antiviral  therapy 
(magnification × 200). A1 and A2: Liver tissue of patients who had a complete response to 
antiviral  therapy  by  IFN-  displayed  a  near  normal  hepatic  lobule  structure,  arrayed 
radiatively around the central vein, the Disse cavity was clear and well-distributed, and 
there was no obvious periportal inflammatory cell infiltration. B1 and B2: Liver tissue of 
patients who had non-response to antiviral therapy by IFN- showed hepatocytes with 
degeneration in hepatic lobule and periportal inflammatory cell infiltration. 
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3.5. STAT-1 and APOBEC3G Expression in the Liver Tissue of CHB Patients Who Had Different 
Responses to IFN- 
The results of both RT-PCR and Western blot showed that STAT-1 and APOBEC3G expression 
levels in the liver tissue of the patients in group A were significantly higher than that of the patients in 
group B, which revealed that the CHB patients with a complete response to antiviral therapy by IFN- 
had a higher expression of STAT-1 and APOBEC3G in the liver, while the expression levels of STAT-1 
and APOBEC3G in the liver of the patients without response to IFN- were significantly lower (Figure 4). 
Figure 4. Expression of STAT-1 and APOBEC3G in liver tissue of the patients who had 
complete  response,  or  no  response  to  antiviral  therapy  by  IFN-  after  treatment. 
(A) RT-PCR electrophotogram of STAT-1 mRNA and APOBE3G mRNA. (B) Detection of 
STAT-1  mRNA  by  real-time  fluorescent  quantitative  RT-PCR.  (C)  Detection  of 
APOBEC3G  mRNA  by  real-time  fluorescent  quantitative  RT-PCR.  (D)  Detection  of 
STAT-1 protein and APOBEC3G protein by Western blot. A1-A5: Five patients who had a 
complete response to IFN-; B1-B8: Eight patients who had non-response to IFN-.   
 
4. Discussion 
In this study, the results showed that expression of APOBEC3G was very low in HepG2.2.15 cells, 
but IFN- was able to induce HepG2.2.15 cells to express APOBEC3G at a high level. Moreover, Int. J. Mol. Sci. 2010, 11                         
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APOBEC3G expression levels increased is a dose- or time-dependent manner within a certain range in 
HepG2.2.15 cells after the treatment with IFN-. These results agree with the findings of Tanaka [19] 
and Bonvin [20]. It is suggested that under normal circumstances, the liver cells may not express 
APOBEC3G, or the expression is relatively low, but cytokines such as IFN- can induce production of 
APOBEC3G during the course of HBV infection. 
The  results  of  this  study  demonstrated  that  IFN-  suppressed  HBV  replication  and  expression 
markedly in HepG2.2.15 cells, and simultaneously enhanced APOBEC3G expression. Moreover, this 
study also showed that the CHB patients with complete response to antiviral therapy with IFN- had a 
higher APOBEC3G expression in the liver, while the levels of APOBEC3G expression in the liver of the 
patients without response to IFN- treatment were significantly lower. Previous studies have revealed 
that APOBEC3G also plays a role in inhibiting HBV replication [5–8], so the data of our study suggest 
that  the  anti-HBV  effects  of  IFN-  could  be  performed  by  enhancing  intracellular  APOBEC3G 
expression, which probably is one of the antiviral mechanisms of IFN-. 
However, recent studies demonstrated that in spite of the induction of APOBEC3G in hepatoma cells 
exposed  to  IFNs,  the  cytokine-mediated  inhibition  of  HBV  replication  is  not  affected  when  the 
expression of APOBEC3G is suppressed by combining RNA interference and the Vif protein of HIV-1 
[21]. The studies further demonstrated that in HBV-transgenic murine APOBEC3 (muA3) knockout 
mice,  IFN  induction  blocked  HBV  DNA  production  as  efficiently  as  in  control  HBV-transgenic 
muA3-competent animals [22]. From these data, it is concluded that IFN does not exert its antiviral 
effect through induction of APOBEC3, which suggest that APOBEC3 is not an essential mediator of the 
IFN-mediated inhibition of HBV in vivo. The downstream effectors of the anti-HBV effect of IFN thus 
remain to be identified in further studies.  
While demonstrating that APOBEC3G is not required for the inhibition of HBV by IFN- both in cell 
culture and in transgenic mice, these results do not imply that antiviral APOBEC3G have no relevance 
for HBV biology and therapy. This study showed that the APOBEC3G protein is weakly expressed in 
HepG2.2.15 cells, but its expression levels increased in a dose- or time-dependent manner in IFN-treated 
HepG2.2.15  cells.  So  APOBEC3G  may  have  a  greater  impact  on  HBV  replication  upon  stronger 
expression, which may occur in the infected liver. Thus, it is not excluded that APOBEC3G acts in 
concert with other yet-undefined IFN-induced effectors during the clearance of HBV in vivo. 
To assess further the role of  APOBEC3G in  the  IFN-mediated clearance of HBV, it might  be 
revealing to compare levels of APOBEC3G in the livers of uninfected, acutely infected, and chronically 
infected individuals. Informative data might also be obtained by looking at possible interindividual 
differences in the sequences of APOBEC3G promoters, particularly with respect to IFN-responsive 
elements. As well, an evaluation of the sensitivity of HBV strains isolated at various stages of the disease 
to APOBEC3G could be indicative. 
The rate of complete response to IFN-α treatment is only unsatisfied 30～33% in the patients with 
chronic hepatitis B (CHB) [23], which is suggested to be related to interferon resistance existing in the 
patients’ bodies. The exact mechanisms of the interferon resistance remains unclear, however, at least 
three factors are involved including host, virus and interferon. It has been suggested that the host factor is 
probably related with down-regulation of IFN receptors or IFN signal transduction [24]. The JAK-STAT 
(Janus kinase-signal transducers and activators of transcription) system is a major signaling pathway of 
alpha interferon-mediated signal transduction and transcriptional activation. Among the various STAT Int. J. Mol. Sci. 2010, 11                         
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proteins, STAT-1 is a key signaling component of IFN-α response [25]. In this pathway, following 
engagement of the heterodimeric receptor at the cell surface with IFN-α, JAKs associated with IFN-α 
receptors  phosphorylate  both  STAT-1  and  STAT-2.  As  a  result,  an  IFN-stimulated  gene  factor  3 
(ISGF3) complex forms, which contains STAT-1, STAT-2 and a third transcription factor called IRF9 
(also known as p48). ISGF3 is translocated from the cytosol into the cell nucleus, in which it binds to 
specific nucleotide sequences called IFN-stimulated response elements (ISREs) in the promoters of 
target genes to induce transcription of those IFN-stimulated genes (ISGs) [26,27].  
In the present study, the results manifested that at the same time of IFN--induced upregulation of 
APOBEC3G expression in HepG2.2.15 cells, a corresponding gradual increase of STAT-1 mRNA and 
protein expression levels was also observed. Whether it is suggested that IFN--induced APOBEC3G 
expression is via JAK-STAT signaling pathway is not yet fully established by our experiments. The 
relationship between them and the exact mechanism remain to be further studied. 
In addition, the differences of STAT-1 expression in liver tissue of patients with chronic hepatitis B 
who had different responses to antiviral therapy with IFN- were also investigated in this study. The 
results showed that the expression levels of STAT-1 in the liver of the CHB patients with a complete 
response to IFN- are significantly higher than that of the patients with non-response to IFN-. It is 
suggested that interferon resistance was related with the down-regulation of STAT-1 expression in the 
patients who had non-response to IFN-. What causes low expression of STAT-1 in the patients with 
non-response to IFN- is unclear. We hypothesize the reasons might be STAT-1 deficiency or/and 
effects of HBV on STAT-1 in those patients, which remain to be further studied to identify the exact 
mechanism of the JAK-STAT signaling pathway in anti-HBV effects of IFN-α. In conclusion, clarifying 
the mechanisms of IFN resistance could provide a new strategy for enhancing the anti-HBV effects of 
IFN-α. 
5. Conclusions 
We report that IFN- suppressed HBV replication and expression markedly in HepG2.2.15 cells, and 
simultaneously enhanced APOBEC3G expression in a dose- or time-dependent manner within a certain 
range. Moreover, a corresponding gradual increase of STAT-1 expression levels was also observed. The 
expression levels of STAT-1 and APOBEC3G in the liver of the CHB patients with a complete response 
to IFN- are significantly higher than those of the patients with non-response to IFN- treatment. The 
study results  suggest  that  inducing intracellular APOBEC3G expression may be one of  anti-HBV 
mechanisms  of  IFN-,  and  IFN--induced  APOBEC3G  expression  may  be  via  the  JAK-STAT 
signaling pathway. Moreover, interferon resistance may be related with the down-regulation of STAT-1 
expression in the patients who had non-response to IFN- treatment. 
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